Pharma BD Deal Intelligence
Lonza's $5.5B all-cash Capsugel acquisition closed clean—full structural integration by January 2018 and record sales/margins the following year—but the strategic rationale collapsed later: by December 2024 Lonza concluded the capsules unit "is not a CDMO business" and moved to divest it to Lone Star Funds for roughly CHF 2.3-3 billion, about half the original price.
Lonza integrated Capsugel well operationally, then spent 2024-2026 unwinding the entire rationale — selling the capsules business for roughly half what it paid, having concluded it was never a CDMO fit.
Full analysis, sources & comparables →Industry consultant James Bruno of Chemical & Pharmaceutical Solutions told FiercePharma the deal creates 'a major addition to competitors to companies like…
Financier Worldwide highlighted the deal's accretive nature, KKR's exit from a 2011 buyout (originally ~$2.4B from Pfizer), and the strategic rationale of…
Pharma Tech highlighted the closing as creating 'a leading integrated solutions provider' with combined offerings spanning microbial fermentation, mammalian…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Lonza completed its acquisition of Capsugel S.A. from KKR for USD 5.5B in cash (including refinancing of ~$2B Capsugel debt), originally announced December 14, 2016 and closed July 6, 2017. The acquisition created a leading integrated CDMO solutions provider, combining Lonza's biologics/manufacturing capabilities with Capsugel's hard capsule and advanced oral delivery technologies.
Lonza integrated Capsugel well operationally, then spent 2024-2026 unwinding the entire rationale — selling the capsules business for roughly half what it paid, having concluded it was never a CDMO fit.
Assessment window: 5yr post-close.
$40.0B Global CDMO market ~$40B in 2017 (Lonza/CDMO segment); empty-capsules market ~$2-3B
Capsugel was the global leader in hard capsule manufacturing (gelatin and HPMC/vegetarian) and advanced oral dosage delivery technologies including lipid multiparticulate (LMP), spray-dried dispersions (SDD) for bioavailability enhancement, and Xcelodose powder micro-dosing. The platform supports formulation of poorly soluble small molecules, extended release, dual release, and inhalation products across pharma, generic, OTC, and nutraceutical end markets.
At deal close (July 2017) Capsugel held the #1 global position in hard capsules with broader specialty oral dosage capabilities. Direct competitors in empty capsules included ACG (India, #2), Qualicaps (Roquette/France-Japan), Suheung (South Korea), and CapsCanada — collectively the top five accounted for >80% of global volume (MarketsandMarkets, https://www.marketsandmarkets.com/ResearchInsight/empty-capsules-market.asp). On the broader CDMO/oral-dosage front, Capsugel competed with Catalent (oral solids and softgels), Patheon (then being acquired by Thermo Fisher for $7.2B weeks before close — see https://www.biopharmadive.com/news/thermo-fisher-to-buy-patheon-in-72b-deal-accelerating-cdmo-consolidation/443066/), and Recipharm. Industry consultant James Bruno told C&EN '...we have a major addition to competitors to companies like Patheon' (FiercePharma, https://www.fiercepharma.com/manufacturing/lonza-bulks-up-5-5b-deal-for-capsugel) — capturing the strategic logic: Lonza, historically a biologics/API CDMO, used Capsugel to build an end-to-end small-molecule + biologics solutions provider, accretive to core EPS in year one with ~$100M target synergies and a 15.1x EV/EBITDA paid multiple. The deal reset the CDMO competitive structure alongside Thermo/Patheon and pre-staged later consolidation (Catalent's bolt-ons, Lonza's spin of CHI segment in 2024-25).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Lonza Group AG / Capsugel S.A. (this deal) | 2016 | $5.5B | 44 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Lonza Group AG / Capsugel S.A. (KKR portfolio) | 2016 | $5.5B | 39 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
← Browse all deals · How we score deals
More: 2016 deals · Lonza Group AG deals · Other deals